The role of ASCT2 in cancer: A review

被引：131

作者：

Liu, Yang ^{[1
]}

Zhao, Tingli ^{[2
]}

Li, Zhengzheng ^{[1
]}

Wang, Lai ^{[2
]}

Yuan, Shengtao ^{[2
]}

Sun, Li ^{[1
]}

机构：

[1] China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing, Jiangsu, Peoples R China

[2] China Pharmaceut Univ, Jiangsu Ctr Pharmacodynam Res & Evaluat, Nanjing, Jiangsu, Peoples R China

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2018年 / 837卷

基金：

中国国家自然科学基金;

关键词：

Glutamine metabolism; ASCT2; SLC1A5; Cancer research; ACID TRANSPORTER ASCT2; TARGETING GLUTAMINE-METABOLISM; CELL LUNG-CANCER; BREAST-CANCER; ANTITUMOR EFFICACY; MAMMALIAN TARGET; GASTRIC-CANCER; GROWTH; EXPRESSION; SURVIVAL;

D O I：

10.1016/j.ejphar.2018.07.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Reorganization of cellular metabolism is one of the hallmarks of cancer and many tumors show high glucose uptake and glutamine addiction. Glutamine is imported by the SLC family transporters from the micro-environment, and ASCT2 (encoded by the SLC1A5 gene) is recognized as a primary transporter. Of note, ASCT2 is overexpressed in different cancers and is closely related to poor prognosis. Nonetheless, the mechanisms regulating ASCT2 activity has not been elucidated. Moreover, several inhibitors of ASCT2 have emerged and shown a surprising antitumor effect. In conclusion, this review describes the function, regulatory mechanism, and inhibitors of ASCT2 in cancer, suggesting that high expression of ASCT2 is a promising prognostic marker and a potential drug target.

引用

页码：81 / 87

页数：7

共 45 条

[1] Redox control of glutamine utilization in cancer [J].

Alberghina, L. ;

Gaglio, D. .

CELL DEATH & DISEASE, 2014, 5 :e1561-e1561

[2] The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer [J].

Bjersand, Kathrine ;

Seidal, Tomas ;

Sundstrom-Poromaa, Inger ;

Akerud, Helena ;

Skirnisdottir, Ingiridur .

PLOS ONE, 2017, 12 (06)

[3] Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells [J].

Broer, Angelika ;

Rahimi, Farid ;

Broer, Stefan .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (25) :13194-13205

[4] Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer [J].

Bromberg, Kenneth D. ;

Kluger, Harriet M. ;

Delaunay, Agnes ;

Abbas, Sabiha ;

DiVito, Kyle A. ;

Krajewski, Stan ;

Ronai, Ze'ev .

CANCER RESEARCH, 2007, 67 (17) :8172-8179

[5] Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer [J].

Brown, Kristin K. ;

Spinelli, Jessica B. ;

Asara, John M. ;

Toker, Alex .

CANCER DISCOVERY, 2017, 7 (04) :391-399

[6]

Cai Canfeng, 2017, Zhonghua Wei Chang Wai Ke Za Zhi, V20, P450

[7] GPNA inhibits the sodium-independent transport system L for neutral amino acids [J].

Chiu, Martina ;

Sabino, Cosimo ;

Taurino, Giuseppe ;

Bianchi, Massimiliano G. ;

Andreoli, Roberta ;

Giuliani, Nicola ;

Bussolati, Ovidio .

AMINO ACIDS, 2017, 49 (08) :1365-1372

[8] Targeting Glutamine Metabolism for Cancer Treatment [J].

Choi, Yeon-Kyung ;

Park, Keun-Gyu .

BIOMOLECULES & THERAPEUTICS, 2018, 26 (01) :19-28

[9] Epigenetic silencing of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism [J].

Dong, J. ;

Xiao, D. ;

Zhao, Z. ;

Ren, P. ;

Li, C. ;

Hu, Y. ;

Shi, J. ;

Su, H. ;

Wang, L. ;

Liu, H. ;

Li, B. ;

Gao, P. ;

Qing, G. .

ONCOGENESIS, 2017, 6 :e356-e356

[10] Metabolic reprogramming of the tumor [J].

Ferreira, L. M. R. ;

Hebrant, A. ;

Dumont, J. E. .

ONCOGENE, 2012, 31 (36) :3999-4011

← 1 2 3 4 5 →